MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why AYTU Stock advanced +0.51% Today — RQD Quant Desk Flash
$1.98 +0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.98
Aytu BioPharma Inc. (AYTU) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $21.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.98 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AYTU)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY AYTU SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)
20D Institutional Volume Accumulation (±9.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.03+0.5% Next Q
49
Q2 (-2Q)Grade D$2.04-6.9% Next Q
46
Q3 (-1Q)Grade D$1.90+4.2% Next Q
44
CurrentGrade D-$1.98-7.2% Hist 90D α
41
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AYTU Turnaround Squeeze
While AYTU currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.10) and Max Pain ($2.08) forces dealer call-delta covering toward $3.22.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AYTU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AYTU Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AYTU Stock advanced +0.51% Today — RQD Quant Desk Flash
Aytu BioPharma Inc. (AYTU) advanced +0.51% to $1.98, trading at 14% of its 52-week range ($1.8 – $3.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 14% of its 52-week range ($1.8 – $3.07) with RSI-14 at 42 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.5% around $1.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 69% gross margin and $0 annual free cash flow.
Live AYTU Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AYTU)
- ✓Walkthrough of AYTU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AYTU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.26%▼ DESCENDING CHANNEL
2026-10-30O $1.98H $2.02L $1.90C $1.98VOL 97.3K
RES: $2.25SUP: $1.79SMA50: $2.10SMA200: $2.32
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AYTU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +1.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AYTU today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AYTU. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AYTU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AYTU)
Health Care Rank #623 of 1016
⚔️ BYSI vs AYTU Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AYTU vs. BYSI, TXMD, ATOS, QNTM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aytu BioPharma Inc. (AYTU) ranks #623 by composite RQD confidence (41/100, grade D-) and #826 by equity capitalization ($21.5M). Within this direct 5-issuer industry benchmark cohort, AYTU leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with AYTU at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AYTU
ACTIVE
Aytu BioPharma Inc. | D- | 41/100 | — | 69.0% | -35.0% | +0.51% | $21.5M | Benchmark Subject |
| BYSI BeyondSpring Inc. | D- | 42/100 | — | — | -35.0% | -1.49% | $21.2M | /bysi-vs-aytu → |
| TXMD TherapeuticsMD Inc. | D | 48/100 | — | — | -12.9% | +2.24% | $21.2M | /txmd-vs-aytu → |
| ATOS Atossa Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -5.91% | $22.3M | /atos-vs-aytu → |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | D+ | 58/100 | — | — | — | +2.95% | $20.7M | /qntm-vs-aytu → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001385818In its most recent audited fiscal period (FY2025, filed 2025-06-30), Aytu BioPharma Inc. (AYTU) reported GAAP revenue of $66.4M (+1.8% vs. FY2024 revenue of $65.2M , and -38.2% cumulative change since FY2023) , GAAP net income of -$13.6M, operating cash flow of -$1.9M, and free cash flow of -$2.2M (-26.1% YoY). On the balance sheet, AYTU closed FY2025 with $122.0M in total assets against $10.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $66.4M | -$13.6M | -$1.9M | -$2.2M | $122.0M | $10.0M |
| FY2024 (FY) | 2024-06-30 | $65.2M | -$15.8M | -$1.4M | -$1.7M | $116.2M | $10.0M |
| FY2023 (FY) | 2023-06-30 | $107.4M | -$17.1M | -$5.1M | -$5.1M | — | — |
3. AYTU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AYTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Aytu BioPharma Inc. (NASDAQ: AYTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.98 (+0.51% 1D, market cap $21.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AYTU ranks #623 in composite RQD confidence.
How does AYTU compare to BYSI and TXMD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AYTU carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 69.0%, and ROIC of -35.0%. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M) and TXMD (TherapeuticsMD Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -12.9%, cap $21.2M). Among the 5-stock peer group, AYTU leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AYTU?
Per AYTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001385818), Aytu BioPharma Inc. generated $66.4M in revenue (+1.8% YoY), -$13.6M in net income, and -$2.2M in free cash flow against $122.0M in total assets and $10.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AYTU trading relative to its 50-day, 200-day, and 52-week technical levels?
AYTU last traded at $1.98 (+0.51% on volume of 9,467 shares), positioning the stock -5.71% below its 50-day simple moving average ($2.10) and -14.66% below its 200-day simple moving average ($2.32). Across its 52-week range of $1.80 to $3.07, AYTU sits at the 14.2% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($1.79 to $2.17).
AYTU Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AYTU stock moving today?
Why AYTU Stock advanced +0.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.